Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Recurrent or metastatic TNBC patients;
TNBC defined by immunohistochemistry as ER\<1%, PR\<1%, Her2=0\~1+, or 2+ while HER2 Fish test shows no amplification；
Previous received no or only first line chemotherapy treatment for recurrent or metastatic TNBC；When the time between cancer metastasis and the end of adjuvant chemotherapy exceeds 1 year, the systemic chemotherapy for metastasis treatment is recorded as first-line treatment; When less than 1year, the systemic chemotherapy for metastasis treatment is recorded as second-line treatment；
ages 18 to 75 years at the time of signing the informed consent form (ICF);
Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1;
expected survival of ≥3 months; at least one measurable lesion per RECIST (version1.1);
acceptable renal and liver function;
You may not be if
They had received ICIs (i.e., anti-PD-1 antibodies, anti-PD-L1 antibodies, and anti-CTLA-4 antibodies.)；
Patients with active central nervous system (CNS) metastatic lesions or meningeal metastases；
Patients with an active autoimmune disease that requires systemic treatment in the past two years；
A known history of primary immunodeficiency；
Pregnant or lactating women；
Previous or current abnormalities of any disease, treatment, laboratory tests may confuse the study results, affect the subject's participation in the study
Clareo Health | Cadonilimab Combined With Chemotherapy as First or Second Line Treatment in Recurrent or Metastatic Triple Negative Breast Cancer
